USA flag logo/image

An Official Website of the United States Government

Drug discovery of anti-ADDL therapeutics for Alzheimer's

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
75819
Program Year/Program:
2005 / SBIR
Agency Tracking Number:
AG026951
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals, Inc. 385 Oyster Point Blvd. South San Francisco, CA 94080
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2005
Title: Drug discovery of anti-ADDL therapeutics for Alzheimer's
Agency: HHS
Contract: 1R43AG026951-01
Award Amount: $183,750.00
 

Abstract:

DESCRIPTION (provided by applicant): Recent evidence suggests that the primary cause of Alzheimer's disease is the progressive accumulation of neurotpxic oligomeric assemblies of the Abeta 1-42 protein. These neurotoxic oligomeric species are known as ADDLs (Ab-derived diffusible ligands). In Tg2576 AD mice, a transgenic Alzheimer's disease animal model, memory performance declines as ADDL levels increase. Human patients with Alzheimer's disease show a 70-fold elevation in ADDL levels relative to unaffected age-matched controls. ADDLs affect memory by directly interfering with synaptic function, which eventually results in synaptic loss over time. This evidence suggests that small molecule, ADDL-directed therapeutics might prevent ADDL-induced cognitive deficits, and slow or reverse disease progression in humans. This stands in contrast to current FDA-approved drugs, which treat the symptoms and not the underlying cause of Alzheimer's disease. The most promising approach to ADDL-directed therapeutics is to prevent ADDL formation by blocking assembly of the Abeta 1-42 protein. The subject of this proposal is to establish and validate a cascade of primary and secondary chemical screens and screen a representative CNS targeted chemical library to identify small molecules that block ADDL assembly. In Phase I, we propose to develop and validate a homogeneous ADDL assembly blocker screening assay, conduct molecular dynamics simulations to build an ADDL structural model, and carry out pilot screening of a selected small molecule library.

Principal Investigator:

Grant A. Krafft
8474176538
GKRAFFT@ACUMENPHARM.COM

Business Contact:

William Goure
6508757700
WOURE@ACUMENPHARM.COM
Small Business Information at Submission:

Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals, Inc. 385 Oyster Point Blvd. South San Francisco, CA 94080

EIN/Tax ID: 364108129
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No